Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
W̱JOȽEȽP, UNCEDED TERRITORY OF W̱SÁNEĆ NATION / BRENTWOOD BAY, B.C., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Today, on International Mother Language Day, Indigenous-led technology platform...
-
VANCOUVER, British Columbia, Feb. 14, 2024 (GLOBE NEWSWIRE) -- RevoluGROUP Canada Inc. (TSX-V: REVO), (Frankfurt: IJA2) (the “Company”) announces that Daniel Hernandez, Director of RevoluGROUP has...
-
Vancouver, BC, Feb. 14, 2024 (GLOBE NEWSWIRE) -- RevoluGROUP Canada Inc. (TSX-V: REVO), (Frankfurt: IJA2) (the “Company”) announces that Daniel Hernandez, Director of RevoluGROUP has decided to step...
-
VANCOUVER, British Columbia, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Christina Lake Cannabis Corp. (CSE: CLC) (OTCQB: CLCFF) (FRANKFURT:CLB), (the “Company” or “Christina Lake Cannabis” or “CLC”), a...
-
Washington, D.C., Feb. 09, 2024 (GLOBE NEWSWIRE) -- Today, the New Civil Liberties Alliance filed a petition for a writ of certiorari, urging the U.S. Supreme Court to hear Metal Conversion Techs....
-
Vancouver, BC, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Bessor Minerals Inc. (NEX:BST.H) ("Bessor") is pleased to announce that the TSX Venture Exchange (the "TSXV") has granted final acceptance regarding...
-
Dublin, Feb. 05, 2024 (GLOBE NEWSWIRE) -- The "Valeo 2024 Canadian Law Firm Hourly Rate Report" report has been added to ResearchAndMarkets.com's offering. The legal industry is set for a...
-
VANCOUVER, British Columbia, Feb. 04, 2024 (GLOBE NEWSWIRE) -- Christina Lake Cannabis Corp. (CSE: CLC) (OTCQB: CLCFF) (FRANKFURT:CLB) (the “Company” or “Christina Lake Cannabis” or “CLC”), a...
-
Vancouver (Canada) and Santa Cruz de Tenerife (Spain), Jan. 15, 2024 (GLOBE NEWSWIRE) -- RevoluPAY EP S.L. (“RevoluPAY”), a wholly owned subsidiary of RevoluGROUP Canada Inc. (TSX-V: REVO),...
-
— NDA accepted and granted Priority Review following its Breakthrough Therapy designation granted in January 2022 — — NDA is supported by data from successful Phase III ESLIM-01 trial in patients...